Skip to main content

Advertisement

Open Peer Review Reports for: Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
11 Feb 2018 Submitted Original manuscript
10 Aug 2018 Author responded Author comments - Nikolas von Bubnoff
Resubmission - Version 2
10 Aug 2018 Submitted Manuscript version 2
28 Oct 2018 Author responded Author comments - Nikolas von Bubnoff
Resubmission - Version 3
28 Oct 2018 Submitted Manuscript version 3
Publishing
5 Nov 2018 Editorially accepted
19 Nov 2018 Article published 10.1186/s12885-018-5045-7

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement